

Peter Gibson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1968270/publications.pdf>

Version: 2024-02-01

317
papers

22,548
citations

8159

76
h-index

9839

141
g-index

322
all docs

322
docs citations

322
times ranked

15595
citing authors

#	ARTICLE	IF	CITATIONS
1	A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 146, 67-75.e5.	0.6	989
2	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 85-95.	0.6	753
3	No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates. <i>Gastroenterology</i> , 2013, 145, 320-328.e3.	0.6	676
4	Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, 508-514.	0.2	606
5	Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 96-109.e1.	0.6	605
6	Diets that differ in their FODMAP content alter the colonic luminal microenvironment. <i>Gut</i> , 2015, 64, 93-100.	6.1	552
7	Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 252-258.	1.4	489
8	Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. <i>Gut</i> , 1993, 34, 386-391.	6.1	484
9	Dietary Triggers of Abdominal Symptoms in Patients With Irritable Bowel Syndrome: Randomized Placebo-Controlled Evidence. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 765-771.	2.4	477
10	Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1366-1373.	1.4	476
11	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet, The</i> , 2015, 385, 1406-1417.	6.3	475
12	Fructose Malabsorption and Symptoms of Irritable Bowel Syndrome: Guidelines for Effective Dietary Management. <i>Journal of the American Dietetic Association</i> , 2006, 106, 1631-1639.	1.3	356
13	Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 15-34.	1.9	339
14	Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. <i>Gastroenterology</i> , 2018, 154, 529-539.e2.	0.6	317
15	Review article: insights into colonic protein fermentation, its modulation and potential health implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 181-196.	1.9	305
16	Personal view: food for thought - western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1399-1409.	1.9	295
17	Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 874-882.	1.9	295
18	Measurement of Short-Chain Carbohydrates in Common Australian Vegetables and Fruits by High-Performance Liquid Chromatography (HPLC). <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 554-565.	2.4	292

#	ARTICLE	IF	CITATIONS
19	Quantification of fructans, galacto-oligosaccharides and other short-chain carbohydrates in processed grains and cereals. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 154-176.	1.3	274
20	Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. <i>Gastroenterology</i> , 2016, 151, 110-119.	0.6	259
21	Systematic review: exercise-induced gastrointestinal syndrome implications for health and intestinal disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 246-265.	1.9	258
22	Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 8-14.	0.6	256
23	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. <i>Gastroenterology</i> , 2015, 148, 938-947.e1.	0.6	241
24	A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. <i>Nature Electronics</i> , 2018, 1, 79-87.	13.1	240
25	Fructan and Free Fructose Content of Common Australian Vegetables and Fruit. <i>Journal of Agricultural and Food Chemistry</i> , 2007, 55, 6619-6627.	2.4	237
26	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014, 63, 433-441.	6.1	222
27	Short-Chain Carbohydrates and Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2013, 108, 707-717.	0.2	218
28	Nutritional inadequacies of the gluten-free diet in both recently diagnosed and long-term patients with coeliac disease. <i>Journal of Human Nutrition and Dietetics</i> , 2013, 26, 349-358.	1.3	217
29	Small intestinal bacterial overgrowth in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 535-540.	1.1	217
30	Review article: fructose malabsorption and the bigger picture. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 349-363.	1.9	208
31	Systematic review: the evidence base for long-term management of coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1042-1066.	1.9	177
32	Food Components and Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, 1158-1174.e4.	0.6	173
33	Does butyrate protect from colorectal cancer?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 209-218.	1.4	171
34	Systematic review: fatigue in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 131-143.	1.9	171
35	Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e164.	1.3	170
36	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	2.4	161

#	ARTICLE	IF	CITATIONS
37	Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. <i>Gut</i> , 2020, 69, 841-851.	6.1	160
38	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1557-1564.e1.	2.4	157
39	Food Choice as a Key Management Strategy for Functional Gastrointestinal Symptoms. <i>American Journal of Gastroenterology</i> , 2012, 107, 657-666.	0.2	156
40	Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?. <i>Gut</i> , 2016, 65, 169-178.	6.1	154
41	Wheat bran affects the site of fermentation of resistant starch and luminal indexes related to colon cancer risk: a study in pigs. <i>Gut</i> , 1999, 45, 840-847.	6.1	147
42	FODMAPs: food composition, defining cutoff values and international application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 53-61.	1.4	146
43	Different fibers have different regional effects on luminal contents of rat colon. <i>Gastroenterology</i> , 1991, 101, 1274-1281.	0.6	132
44	Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 165-174.	1.9	131
45	Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 261-268.	1.4	130
46	Genome mapping of seed-borne allergens and immunoresponsive proteins in wheat. <i>Science Advances</i> , 2018, 4, eaar8602.	4.7	130
47	Increased gut permeability in Crohn's disease: is TNF the link?. <i>Gut</i> , 2004, 53, 1724-1725.	6.1	123
48	Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 414-428.	1.9	123
49	Practical insights into gluten-free diets. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 580-591.	8.2	119
50	Wheat bran suppresses potato starch-potentiated colorectal tumorigenesis at the aberrant crypt stage in a rat model. <i>Gastroenterology</i> , 1996, 110, 508-514.	0.6	118
51	Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. <i>Gut</i> , 2018, 67, 973-985.	6.1	116
52	Intestinal gases: influence on gut disorders and the role of dietary manipulations. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 733-747.	8.2	116
53	Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 415-429.e15.	0.6	114
54	Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. <i>PLoS ONE</i> , 2019, 14, e0210728.	1.1	109

#	ARTICLE	IF	CITATIONS
55	Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. <i>Gastroenterology</i> , 2001, 120, 889-899.	0.6	108
56	Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 447-459.	1.9	107
57	Gut-training: the impact of two weeks repetitive gut-challenge during exercise on gastrointestinal status, glucose availability, fuel kinetics, and running performance. <i>Applied Physiology, Nutrition and Metabolism</i> , 2017, 42, 547-557.	0.9	106
58	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 380-390.e1.	2.4	104
59	Human intestinal gas measurement systems: in vitro fermentation and gas capsules. <i>Trends in Biotechnology</i> , 2015, 33, 208-213.	4.9	102
60	Randomised clinical trial: gluten may cause depression in subjects with non-coeliac gluten sensitivity – an exploratory clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1104-1112.	1.9	100
61	Development and Validation of a Comprehensive Semi-Quantitative Food Frequency Questionnaire that Includes FODMAP Intake and Glycemic Index. <i>Journal of the American Dietetic Association</i> , 2010, 110, 1469-1476.	1.3	99
62	Design of Clinical Trials Evaluating Dietary Interventions in Patients With Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2013, 108, 748-758.	0.2	99
63	Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 819-834.	1.4	99
64	The impact of exertional-heat stress on gastrointestinal integrity, gastrointestinal symptoms, systemic endotoxin and cytokine profile. <i>European Journal of Applied Physiology</i> , 2018, 118, 389-400.	1.2	97
65	Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2014, 27, 263-275.	1.3	96
66	Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 598-606.	0.6	95
67	Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 45-55.	1.4	92
68	Review article: vitamin D and inflammatory bowel disease – established concepts and future directions. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 324-344.	1.9	91
69	Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. <i>Gastroenterology</i> , 1997, 113, 487-496.	0.6	90
70	Abnormal fibre usage in UC in remission. <i>Gut</i> , 2015, 64, 562-570.	6.1	89
71	Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. <i>Journal of Cellular Physiology</i> , 2000, 183, 347-354.	2.0	87
72	Association of Circulating Vitamin D Concentrations with Intestinal but Not Systemic Inflammation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2634-2643.	0.9	87

#	ARTICLE	IF	CITATIONS
73	Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1104-1115.	1.9	87
74	Characterization of Adults With a Self-Diagnosis of Nonceliac Gluten Sensitivity. <i>Nutrition in Clinical Practice</i> , 2014, 29, 504-509.	1.1	85
75	Use of the low-FODMAP diet in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 40-42.	1.4	85
76	Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2021, 160, 47-62.	0.6	81
77	Dietary fibre: a roughage guide. <i>Internal Medicine Journal</i> , 2003, 33, 291-296.	0.5	80
78	Pilot study on the effect of reducing dietary FODMAP intake on bowel function in patients without a colon. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1522-1528.	0.9	80
79	Colonic epithelial cell activation and the paradoxical effects of butyrate. <i>Carcinogenesis</i> , 1999, 20, 539-544.	1.3	78
80	Carbohydrate and protein intake during exertional heat stress ameliorates intestinal epithelial injury and small intestine permeability. <i>Applied Physiology, Nutrition and Metabolism</i> , 2017, 42, 1283-1292.	0.9	76
81	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493.	2.4	76
82	Review article: FODMAPS, prebiotics and gut health—the FODMAP hypothesis revisited. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 233-246.	1.9	75
83	Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1134-1142.	1.4	72
84	Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. <i>Hepatology</i> , 1992, 15, 1054-1059.	3.6	71
85	Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1019-1024.	1.9	71
86	Dietary management of IBD—insights and advice. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 133-146.	8.2	71
87	Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 559-569.	1.0	70
88	Contrasting effects of butyrate on the expression of phenotypic markers of differentiation in neoplastic and non-neoplastic colonic epithelial cells in vitro. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 165-172.	1.4	69
89	Cognitive impairment in coeliac disease improves on a gluten-free diet and correlates with histological and serological indices of disease severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 160-170.	1.9	69
90	Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2518-2525.e1.	2.4	64

#	ARTICLE	IF	CITATIONS
91	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 504-514.	1.9	63
92	Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 201-205.	0.4	63
93	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 753-762.	1.9	63
94	Review article: emulsifiers in the food supply and implications for gastrointestinal disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 41-50.	1.9	63
95	Venous and arterial disease in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1095-1113.	1.4	61
96	Food intolerance in functional bowel disorders. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 128-131.	1.4	60
97	Interleukin-8 stimulates the migration of human colonic epithelial cells in vitro. <i>Clinical Science</i> , 1999, 97, 385-390.	1.8	59
98	Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 626-634.	0.6	59
99	History of the low FODMAP diet. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 5-7.	1.4	59
100	Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorption. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 318-326.	0.8	58
101	The Low FODMAP Diet and Its Application in East and Southeast Asia. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 459-470.	0.8	58
102	Is Gluten a Cause of Gastrointestinal Symptoms in People Without Celiac Disease?. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 631-638.	2.4	56
103	Intestinal Gas Capsules: A Proof-of-Concept Demonstration. <i>Gastroenterology</i> , 2016, 150, 37-39.	0.6	56
104	The Impact of Mild Heat Stress During Prolonged Running On Gastrointestinal Integrity, Gastrointestinal Symptoms, Systemic Endotoxin and Cytokine Profiles. <i>International Journal of Sports Medicine</i> , 2018, 39, 255-263.	0.8	56
105	Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome—directions for future research. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 124-139.	1.9	56
106	Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A 5-year longitudinal study from diagnosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 342-349.	1.4	55
107	Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1306-1312.	1.4	53
108	Diarrhoea during enteral nutrition is predicted by the poorly absorbed short-chain carbohydrate (FODMAP) content of the formula. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 925-933.	1.9	53

#	ARTICLE	IF	CITATIONS
109	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 150-161.	1.9	53
110	Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 465-479.	0.6	52
111	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. <i>World Journal of Gastroenterology</i> , 2017, 23, 6385-6402.	1.4	51
112	Objectively measured muscle fatigue in Crohn's disease: Correlation with self-reported fatigue and associated factors for clinical application. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 137-146.	0.6	50
113	Two weeks of repetitive gut challenge reduce exercise-associated gastrointestinal symptoms and malabsorption. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2018, 28, 630-640.	1.3	50
114	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 612-628.	1.9	49
115	B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. <i>PLoS ONE</i> , 2016, 11, e0160103.	1.1	49
116	Effect of butyrate on paracellular permeability in rat distal colonic mucosa <i>ex vivo</i> . <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 873-879.	1.4	48
117	The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 32-35.	1.4	46
118	The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production <i>in vivo</i> in healthy subjects: a pilot trial comparison to concurrent breath analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 646-654.	1.9	46
119	Review article: the role of the autonomic nervous system in the pathogenesis and therapy of IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 720-737.	1.9	45
120	Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective. <i>International Journal of Food Microbiology</i> , 2019, 290, 237-246.	2.1	44
121	Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1017-1026.	1.9	43
122	Consensus statements on Crohn's disease. Part 2: Management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 56-68.	1.4	42
123	Evaluation of a 12-week targeted vitamin D supplementation regimen in patients with active inflammatory bowel disease. <i>Clinical Nutrition</i> , 2018, 37, 1375-1382.	2.3	42
124	A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: A case for subcutaneous administration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 954-958.	1.4	41
125	Splenomegaly: an insensitive sign of portal hypertension. <i>Australian and New Zealand Journal of Medicine</i> , 1990, 20, 771-774.	0.5	40
126	Strategies to Manage Gastrointestinal Symptoms Complicating Enteral Feeding. <i>Journal of Parenteral and Enteral Nutrition</i> , 2009, 33, 21-26.	1.3	40

#	ARTICLE	IF	CITATIONS
127	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1135-1145.	1.9	40
128	Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by Lactase Treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 124-134.	0.2	40
129	Dietary management of adults with IBD – the emerging role of dietary therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 652-669.	8.2	40
130	Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders. <i>United European Gastroenterology Journal</i> , 2017, 5, 284-292.	1.6	39
131	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 289-297.	0.6	39
132	Augmentin-induced jaundice with a fatal outcome. <i>Medical Journal of Australia</i> , 1992, 156, 285-286.	0.8	39
133	Drug-induced gastrointestinal disorders. <i>Frontline Gastroenterology</i> , 2014, 5, 49-57.	0.9	38
134	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AZATHIO Study). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1092-1102.	1.9	38
135	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1551-1562.	1.9	38
136	Controversies and Recent Developments of the Low-FODMAP Diet. <i>Gastroenterology and Hepatology</i> , 2017, 13, 36-45.	0.2	38
137	Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?. <i>Gut</i> , 2005, 54, 900-903.	6.1	37
138	Non-coeliac gluten sensitivity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 86-89.	1.4	37
139	Seasonal recurrence of food bolus obstruction in eosinophilic esophagitis. <i>Internal Medicine Journal</i> , 2015, 45, 939-943.	0.5	36
140	Functional bowel symptoms and diet. <i>Internal Medicine Journal</i> , 2013, 43, 1067-1074.	0.5	34
141	Long-term outcomes of colectomy surgery among patients with ulcerative colitis. <i>SpringerPlus</i> , 2015, 4, 573.	1.2	34
142	Other Dietary Confounders: FODMAPS et al.. <i>Digestive Diseases</i> , 2015, 33, 269-276.	0.8	34
143	Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e168.	1.3	34
144	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860.	0.9	34

#	ARTICLE	IF	CITATIONS
145	Neuromodulation via Interferential Electrical Stimulation as a Novel Therapy in Gastrointestinal Motility Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 19-29.	0.8	33
146	The concept of small intestinal bacterial overgrowth in relation to functional gastrointestinal disorders. <i>Nutrition</i> , 2010, 26, 1038-1043.	1.1	32
147	Fructose malabsorption syndrome. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 1.	1.3	31
148	Republished: Drug-induced gastrointestinal disorders. <i>Postgraduate Medical Journal</i> , 2014, 90, 411-419.	0.9	31
149	The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882256.	1.4	31
150	Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine. <i>Gut</i> , 2021, 70, 2383-2394.	6.1	31
151	The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation. <i>American Journal of Gastroenterology</i> , 2022, 117, 947-957.	0.2	31
152	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 452-462.	0.6	30
153	Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro. <i>Gastroenterology</i> , 1994, 107, 410-419.	0.6	29
154	Potential of in vivo real-time gastric gas profiling: a pilot evaluation of heat-stress and modulating dietary cinnamon effect in an animal model. <i>Scientific Reports</i> , 2016, 6, 33387.	1.6	29
155	Protective Role of the Epithelium of the Small Intestine and Colon. <i>Inflammatory Bowel Diseases</i> , 1996, 2, 279-302.	0.9	28
156	The Influence of Specific Luminal Factors on the Colonic Epithelium: High-Dose Butyrate and Physical Changes Suppress Early Carcinogenic Events in Rats. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 549-559.	0.7	28
157	How healthy is a gluten-free diet?. <i>British Journal of Nutrition</i> , 2015, 114, 1539-1541.	1.2	28
158	Screening dietary fibres for fermentation characteristics and metabolic profiles using a rapid <i>in vitro</i> approach: implications for irritable bowel syndrome. <i>British Journal of Nutrition</i> , 2021, 126, 208-218.	1.2	27
159	Tacrine-Induced Hepatotoxicity. <i>CNS Drugs</i> , 1995, 4, 168-181.	2.7	26
160	The White Diet is preferred, better tolerated, and non-inferior to a clear fluid diet for bowel preparation: A randomized controlled trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 355-363.	1.4	26
161	Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1061-1073.	1.9	26
162	Protective role of the epithelium of the small intestine and colon. <i>Inflammatory Bowel Diseases</i> , 1996, 2, 279-302.	0.9	25

#	ARTICLE	IF	CITATIONS
163	Dietary practices and FODMAPs in South Asia: Applicability of the low FODMAP diet to patients with irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 365-374.	1.4	25
164	Culture- and metagenomics-enabled analyses of the <i>Methanosphaera</i> genus reveals their monophyletic origin and differentiation according to genome size. <i>ISME Journal</i> , 2018, 12, 2942-2953.	4.4	24
165	Nutritional profile of rodent diets impacts experimental reproducibility in microbiome preclinical research. <i>Scientific Reports</i> , 2020, 10, 17784.	1.6	24
166	Systematic review and meta-analysis: the effects of fermented milk with <i>Bifidobacterium lactis</i> CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 74-88.	1.4	23
167	Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology. <i>Gut Microbes</i> , 2018, 9, 1-13.	4.3	23
168	Uncertain Diagnostic Language Affects Further Studies, Endoscopies, and Repeat Consultations for Patients With Functional Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1735-1741.e1.	2.4	22
169	Naturally occurring dietary salicylates: A closer look at common Australian foods. <i>Journal of Food Composition and Analysis</i> , 2017, 57, 31-39.	1.9	22
170	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 653-661.	0.6	22
171	Inaccuracy of patient-reported descriptions of and satisfaction with bowel actions in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13187.	1.6	22
172	Eosinophilic esophagitis: A clinicopathological review. , 2015, 146, 12-22.		21
173	Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 136-144.e31.	2.4	21
174	Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. <i>Internal Medicine Journal</i> , 2013, 43, 919-926.	0.5	20
175	Adding glucose to food and solutions to enhance fructose absorption is not effective in preventing fructose-induced functional gastrointestinal symptoms: randomised controlled trials in patients with fructose malabsorption. <i>Journal of Human Nutrition and Dietetics</i> , 2017, 30, 73-82.	1.3	20
176	Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 280-288.	0.6	20
177	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 93-102.	0.9	20
178	Successful elevation of circulating acetate and propionate by dietary modulation does not alter T-regulatory cell or cytokine profiles in healthy humans: a pilot study. <i>European Journal of Nutrition</i> , 2020, 59, 2651-2661.	1.8	20
179	Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1174-1184.	1.9	20
180	Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1813-1817.	1.4	19

#	ARTICLE	IF	CITATIONS
181	Not All Effects of a Gluten-Free Diet Are Due to Removal of Gluten. <i>Gastroenterology</i> , 2013, 145, 693.	0.6	18
182	Chronic constipation and abdominal pain: Independent or closely interrelated symptoms?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1294-1301.	1.4	18
183	Randomised clinical trial: transabdominal interferential electrical stimulation vs sham stimulation in women with functional constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 760-769.	1.9	18
184	The hypotensive effect of oral nitroglycerin on portal venous pressure in patients with cirrhotic portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1986, 1, 201-206.	1.4	17
185	Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells. , 2000, 182, 222-231.		17
186	Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1053-1066.	0.6	17
187	Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901275.	1.5	17
188	Microbial Interventions to Control and Reduce Blood Pressure in Australia (MICRoBIA): rationale and design of a double-blinded randomised cross-over placebo controlled trial. <i>Trials</i> , 2021, 22, 496.	0.7	17
189	Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 84-94.	1.9	17
190	Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 700-704.	1.9	17
191	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 6-27.	1.9	17
192	Effect of Topical Butyrate on Rectal Epithelial Kinetics and Mucosal Enzyme Activities. <i>Clinical Science</i> , 1998, 94, 671-676.	1.8	16
193	Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. <i>Frontline Gastroenterology</i> , 2014, 5, 183-189.	0.9	16
194	Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a proof-of-concept study. <i>Journal of Human Nutrition and Dietetics</i> , 2018, 31, 256-265.	1.3	16
195	Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover. <i>Gut</i> , 1998, 43, 656-663.	6.1	15
196	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1462-1473.	0.9	15
197	Protective role of the epithelium of the small intestine and colon. <i>Inflammatory Bowel Diseases</i> , 1996, 2, 279-302.	0.9	15
198	Supplementing Dietary Fibers With a Low FODMAP Diet in Irritable Bowel Syndrome: A Randomized Controlled Crossover Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2112-2120.e7.	2.4	15

#	ARTICLE	IF	CITATIONS
199	Hypermobility-Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1693-1709.	1.4	15
200	How to Implement the 3-Phase FODMAP Diet Into Gastroenterological Practice. <i>Journal of Neurogastroenterology and Motility</i> , 2022, 28, 343-356.	0.8	15
201	Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1328-1330.	1.9	14
202	Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 1108-1114.	0.7	14
203	Designing an in-vitro gas profiling system for human faecal samples. <i>Sensors and Actuators B: Chemical</i> , 2017, 238, 754-764.	4.0	13
204	Referrals to a tertiary hospital: A window into clinical management issues in functional gastrointestinal disorders. <i>JGH Open</i> , 2017, 1, 84-91.	0.7	13
205	Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 652-666.	1.9	13
206	Delivery of Acetate to the Peripheral Blood after Consumption of Foods High in Short-Chain Fatty Acids. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000953.	1.5	13
207	Metabolomics as a tool for diagnosis and monitoring in coeliac disease. <i>Metabolomics</i> , 2015, 11, 980-990.	1.4	12
208	Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). <i>JGH Open</i> , 2018, 2, 217-222.	0.7	12
209	Dietary fat and the faecal microbiome: where collinearity may lead to incorrect attribution of effects to fat. <i>Gut</i> , 2020, 69, 1718.2-1718.	6.1	12
210	The Low FODMAP Diet for Treatment of Irritable Bowel Syndrome and Other Gastrointestinal Disorders. <i>Gastroenterology and Hepatology</i> , 2013, 9, 450-2.	0.2	12
211	Cell associated urokinase activity and colonic epithelial cells in health and disease.. <i>Gut</i> , 1991, 32, 191-195.	6.1	11
212	Relationship of hydrolase activities to epithelial cell turnover in distal colonic mucosa of normal rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 866-872.	1.4	11
213	Understanding the gluten-free diet for teaching in Australia. <i>Nutrition and Dietetics</i> , 2006, 63, 155-165.	0.9	11
214	For Celiac Disease, Diagnosis Is Not Enough. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 900-901.	2.4	11
215	Alternative investigations for irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 73-77.	1.4	11
216	Adult sucrase-isomaltase deficiency masquerading as IBS. <i>Gut</i> , 2022, 71, 1237-1238.	6.1	11

#	ARTICLE	IF	CITATIONS
217	Diet as a therapeutic tool in chronic gastrointestinal disorders: Lessons from the FODMAP journey. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 644-652.	1.4	11
218	Therapeutic Potential of the 4 Strategies to Sulfide-Reduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study. <i>Journal of Nutrition</i> , 2022, 152, 1690-1701.	1.3	11
219	Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1323-1340.	1.9	11
220	Transcutaneous vagal nerve stimulation protects against stress-induced intestinal barrier dysfunction in healthy adults. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14382.	1.6	11
221	Duplex Doppler ultrasound of the ligamentum teres and portal vein: A clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1991, 6, 61-65.	1.4	10
222	Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 1996, 2, 105-114.	0.9	10
223	Apoptosis or Necrosis-Colonic Epithelial Cell Survival. <i>Novartis Foundation Symposium</i> , 2008, , 133-150.	1.2	10
224	Non-nutritional effects of food: An underutilized and understudied therapeutic tool in chronic gastrointestinal diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 37-40.	1.4	10
225	Poor predictive value of breath hydrogen response for probiotic effects in IBS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1731-1739.	1.4	10
226	Challenges of Quantifying FODMAPs in Enteral Nutrition Formulas: Evaluation of Artifacts and Solutions. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 1262-1271.	1.3	10
227	The Potential of Integrated Nurse-Led Models to Improve Care for People With Functional Gastrointestinal Disorders. <i>Gastroenterology Nursing</i> , 2020, 43, 53-64.	0.2	10
228	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1345-1353.	0.6	9
229	Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1580-1589.	1.4	9
230	Current concepts in the pathogenesis of Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 44-65.	1.4	8
231	Diet Therapy for Irritable Bowel Syndrome: Is a Diet Low in FODMAPS Really Similar in Efficacy to Traditional Dietary Advice?. <i>Gastroenterology</i> , 2016, 150, 1046-1047.	0.6	8
232	Editorial: rethinking predictors of response to the low FODMAP diet – should we retire fructose and lactose breath-hydrogen testing and concentrate on visceral hypersensitivity?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1281-1282.	1.9	8
233	White Diet with split-dose Picosalax is preferred, better tolerated, and non-inferior to day-before clear fluids with polyethylene glycol plus sodium picosulfate-magnesium citrate for morning colonoscopy: A randomized, non-inferiority trial. <i>JGH Open</i> , 2017, 1, 38-43.	0.7	8
234	lluminating dark depths. <i>Science</i> , 2018, 360, 856-857.	6.0	8

#	ARTICLE	IF	CITATIONS
235	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1622-1631.	1.1	8
236	Accuracy of Gastrointestinal Ultrasound and Calprotectin in the Assessment of Inflammation and its Location in Patients with an Ileoanal Pouch. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 79-90.	0.6	8
237	A systematic review of psychological treatments to manage fatigue in patients with inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , 2021, 147, 110524.	1.2	8
238	Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis. <i>MDM Policy and Practice</i> , 2021, 6, 238146832097841.	0.5	8
239	IgG and EoE: Too Soon for a Paradigm Shift Away From IgE. <i>Gastroenterology</i> , 2015, 148, 453-454.	0.6	7
240	Easing Concerns About the Low FODMAP Diet in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 153, 886-887.	0.6	7
241	Performance of an algorithm-based approach to the diagnosis and management of functional gastrointestinal disorders: A pilot trial. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13243.	1.6	7
242	A comparison of Doppler flowmetry with conventional assessment of acute changes in hepatic blood flow. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 14-20.	1.4	6
243	Overview of inflammatory bowel disease in Australia in the last 50 years. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, S63-8.	1.4	6
244	Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. <i>Internal Medicine Journal</i> , 2012, 42, 907-912.	0.5	6
245	Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 11379.	1.4	6
246	The Lactulose Breath Test in Irritable Bowel Syndrome: Is It All Hot Air?. <i>Digestive Diseases and Sciences</i> , 2016, 61, 655-657.	1.1	6
247	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 163-171.	0.9	6
248	The Role of Epidemiological Evidence from Prospective Population Studies in Shaping Dietary Approaches to Therapy in Crohn's Disease. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000294.	1.5	6
249	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab <i>in Utero</i> : A Prospective Cohort Study in 107 Children. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1835-1844.	0.6	6
250	PATHOPHYSIOLOGY OF PORTAL HYPERTENSION AND IMPLICATIONS FOR ITS PHARMACOLOGICAL CONTROL. <i>Australian and New Zealand Journal of Medicine</i> , 1989, 19, 172-182.	0.5	5
251	Dietary modulation of colonic mucosal urokinase activity in rats. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 324-330.	1.4	5
252	Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1423-1424.	1.9	5

#	ARTICLE	IF	CITATIONS
253	Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 990-998.	1.4	5
254	Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1280-1287.	0.8	5
255	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 1-15.	1.1	5
256	Lessons from an audit of exclusive enteral nutrition in adult inpatients and outpatients with active Crohn's disease: a single-centre experience. <i>Frontline Gastroenterology</i> , 2023, 14, 6-12.	0.9	5
257	A comparison of duplex Doppler sonography of the ligamentum teres and portal vein with endoscopic demonstration of gastroesophageal varices in patients with chronic liver disease or portal hypertension, or both. <i>Journal of Ultrasound in Medicine</i> , 1992, 11, 327-331.	0.8	4
258	Systemic mastocytosis: a gastroenterological perspective. <i>Frontline Gastroenterology</i> , 2012, 3, 5-9.	0.9	4
259	Semiquantitative assessment of breath hydrogen testing. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1450-1456.	1.4	4
260	Letter: oral fructose - breath hydrogen response, symptoms, both or neither?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 442-443.	1.9	4
261	Reply. <i>Gastroenterology</i> , 2014, 146, 1830-1831.	0.6	4
262	Letter: low FODMAP diet for exercise-induced gastrointestinal syndrome? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1023-1024.	1.9	4
263	Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome? getting the facts right. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 385-386.	1.9	4
264	Is Non-Celiac Rice-Starch Sensitivity as Common in Children as Non-Celiac Gluten Sensitivity?. <i>American Journal of Gastroenterology</i> , 2018, 113, 1254.	0.2	4
265	Efficacy of glutamine in postinfection IBS. <i>Gut</i> , 2019, 68, 1905-1906.	6.1	4
266	Naturally occurring dietary salicylates in the genesis of functional gastrointestinal symptoms in patients with irritable bowel syndrome: Pilot study. <i>JGH Open</i> , 2021, 5, 871-878.	0.7	4
267	Editorial: inaccuracies in attribution of symptoms due to gluten? not just in those with self-reported nonceliac gluten sensitivity. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 402-403.	1.9	4
268	Evaluating tolerability of resistant starch 2, alone and in combination with minimally fermented fibre for patients with irritable bowel syndrome: a pilot randomised controlled cross-over trial. <i>Journal of Nutritional Science</i> , 2022, 11, e15.	0.7	4
269	Measurement of faecal $\text{I}^{\pm}1$ antitrypsin: Methodologies and clinical application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 311-318.	1.4	3
270	Safety of rapid infusion of iron polymaltose: comparative study in 300 patients. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 324-330.	0.5	3

#	ARTICLE	IF	CITATIONS
271	Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 10-11.	1.4	3
272	FODMAPs and carbohydrate intolerance. , 2020, , 371-386.		3
273	Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 419-428.	1.9	3
274	The Reliability and Accuracy of Endoscopic Items and Scores Used in the Assessment of the Ileoanal Pouch and Cuff. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 18-26.	0.6	3
275	Lower gastrointestinal tract. <i>Medical Journal of Australia</i> , 1995, 162, 155-157.	0.8	3
276	Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 613-621.	0.8	3
277	Correspondence. <i>Hepatology</i> , 1988, 8, 1723-1723.	3.6	2
278	Percutaneous transhepatic measurement of the pressure gradient between the portal and hepatic veins. <i>Australian and New Zealand Journal of Medicine</i> , 1993, 23, 374-380.	0.5	2
279	Commentary: sugar intolerances in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 72-72.	1.9	2
280	Editorial: noncoeliac gluten sensitivity - the controversy rages on. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1234-1234.	1.9	2
281	Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1527-1536.	0.6	2
282	Dietary Changes Among Breastfeeding Mothers. <i>Journal of Human Lactation</i> , 2021, 37, 566-576.	0.8	2
283	Anti-TNF± Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy: A Case Series. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	2
284	The FODMAP diet: more than just a symptomatic therapy?. <i>Gut</i> , 2021, , gutjnl-2021-326284.	6.1	2
285	Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 1996, 2, 105-14.	0.9	2
286	Nonspecific ileitis: Impact of histopathology and gastrointestinal ultrasound in achieving the diagnosis of Crohn's disease. <i>JGH Open</i> , 2022, 6, 388-394.	0.7	2
287	Letter: gutâ€“brain axis dysfunction underlies symptom generation in irritable bowel syndromeâ€”a plea for rational interpretation of irrational doses of <sc>FODMAP</sc> s. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 366-367.	1.9	2
288	Reply. <i>Gastroenterology</i> , 2014, 146, 321-322.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Editorial: predicting response to a low FODMAP diet in children. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 775-776.	1.9	1
290	What Gastroenterologists Should Know About Testing Patients With Eosinophilic Esophagitis for Food Allergies. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1029-1030.	2.4	1
291	Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 902-903.	1.9	1
292	Letter: dietary therapy in eosinophilic oesophagitis "do not test, just eliminate and reintroduce the most common food triggers. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 905-906.	1.9	1
293	The Crohn's Disease "Ulcerative Colitis Clinical Appraisal. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 638-639.	2.4	1
294	Sa2038 "Lack of Experimental Reproducibility in Preclinical Research May Be Influenced by the Nutritional Profile of Standard Rodent Chows. <i>Gastroenterology</i> , 2019, 156, S-481.	0.6	1
295	Study design of endoscopic polypectomy on clopidogrel (EPOC): A randomised controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100479.	0.5	1
296	Prebiotics Versus Low FODMAP Diet: An Interpretative Nightmare. <i>Gastroenterology</i> , 2019, 156, 1222.	0.6	1
297	Commentary: recognising the boom in coeliac disease prevalence was more than just increased awareness. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 207-208.	1.9	1
298	Initial experiences of an in-reach service providing iron infusions in residential aged care facilities. <i>Australasian Journal on Ageing</i> , 2020, 39, e454-e459.	0.4	1
299	The Importance of Accurate Phenotyping and Pouchitis Risk and Dietary Assessment When Investigating the Microbial Factors Behind Antibiotic-Dependent Pouchitis. <i>Gastroenterology</i> , 2020, 159, 399-400.	0.6	1
300	Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 692-695.	1.0	1
301	Apoptosis or necrosis--colonic epithelial cell survival. <i>Novartis Foundation Symposium</i> , 2004, 263, 133-45; discussion 145-50, 211-8.	1.2	1
302	Cold snare polypectomy of colorectal polyps >10mm on clopidogrel: Australian and New Zealand randomized controlled trial. <i>Endoscopy International Open</i> , 2022, 10, E745-E752.	0.9	1
303	Letter: progressive weakening of the concept that gluten has a detrimental effect on mental health and gut symptoms in the absence of coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 363-364.	1.9	1
304	Serum enzyme pattern in acute liver disease: Relation to type of cell death. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 419-422.	1.4	0
305	Lower gastrointestinal tract*: 2. Diarrhoea and diverticular disease. <i>Medical Journal of Australia</i> , 1995, 162, 217-219.	0.8	0
306	THE HOST INFLAMMATORY RESPONSE TO HELICOBACTER PYLORI. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, H24-H25.	1.4	0

#	ARTICLE	IF	CITATIONS
307	Commentary: broadening the focus of coeliac management to follow-up strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 112-112.	1.9	0
308	Editorial: a new shift in the paradigm of treatment for the irritable bowel syndrome?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1296-1296.	1.9	0
309	Editorial: management of eosinophilic oesophagitis – efficacy vs. effectiveness. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 199-200.	1.9	0
310	Letter: avoiding misconceptions about elimination diet for eosinophilic oesophagitis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 100-101.	1.9	0
311	Editorial: variability in adalimumab trough and peak serum concentrations – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1476-1477.	1.9	0
312	Letters: low FODMAP diet – directions for future research and the low FODMAP diet is not the only diet for IBS – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1109-1110.	1.9	0
313	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 573-574.	2.4	0
314	Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 510-510.	1.9	0
315	GERD AND H. PYLORI INFECTION. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, H22-H22.	1.4	0
316	Self-Worth Beliefs Predict Willingness to Engage in Psychotherapy for Fatigue in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	0
317	Coeliac disease in 2022. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, .	1.9	0